Dr Reddy's Q3 Profit Beats Estimates Despite YoY Decline; Revenue Surges

• Dr Reddy's Laboratories reported a Q3 net profit of ₹1,209 crore, exceeding the CNBC-TV18 poll estimate of ₹1,132 crore.
• Revenue for the quarter reached ₹8,753 crore, surpassing the estimated ₹8,273 crore, marking a 4.4% YoY increase.
• Despite higher revenue, net profit declined 14.5% year-on-year from ₹1,413 crore, and EBITDA fell 17% YoY.
• North America revenues declined 12% YoY due to lower lenalidomide sales and price erosion, while Europe and India revenues saw significant growth.
• The company launched 30 new products across countries in Q3FY26, with 73 filings pending approval from the US FDA as of December 31, 2025.

Why It Matters: Dr Reddy's Q3 profit beat estimates on strong revenue growth, despite a year-on-year decline in net profit.